The intervention being tested is BNT327, administered in two dose levels, combined with standard chemotherapy drugs such as etoposide, carboplatin, paclitaxel, and topotecan. The purpose is to ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in breast cancer treatment. The involvement of ...

BNT327/PM8002 has shown encouraging efficacy and tolerability in patients across various tumor types, with more than 700 patients treated in clinical trials to date.

BNT327, BioNTech’ s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech, which acquired BNT327 in an $800 million acquisition of China-based biotech Biotheus late last year, has advanced the drug into Phase 3 trials in both small cell and non-small cell lung ...

BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to ...

“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...

BioNTech's BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date.

BioNTech's BNT327 could lead U.S. and European approvals for key cancers, with pivotal data expected in 2025. Ready to turn the market’s comeback into steady cash flow?

BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...